Cytek Biosciences [CTKB] vs Enovis [ENOV] Detailed Stock Comparison

Cytek Biosciences

NASDAQ

Enovis

NYSE

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Cytek Biosciences wins in 8 metrics, Enovis wins in 10 metrics, with 0 ties. Enovis appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric	Cytek Biosciences	Enovis	Better
P/E Ratio (TTM)	374.50	-1.90	Enovis
Price-to-Book Ratio	1.36	0.63	Enovis
Debt-to-Equity Ratio	6.27	56.75	Cytek Biosciences
PEG Ratio	67.17	9.00	Enovis
EV/EBITDA	-12.48	8.41	Cytek Biosciences
Profit Margin (TTM)	-3.27%	-37.80%	Cytek Biosciences
Operating Margin (TTM)	-23.30%	2.41%	Enovis
EBITDA Margin (TTM)	N/A	2.41%	N/A
Return on Equity	-1.67%	-28.25%	Cytek Biosciences
Return on Assets (TTM)	-3.77%	0.89%	Enovis
Free Cash Flow (TTM)	$21.65M	$-67.21M	Cytek Biosciences
1-Year Return	-22.80%	-34.47%	Cytek Biosciences
Price-to-Sales Ratio (TTM)	2.62	0.74	Enovis
Enterprise Value	$274.37M	$3.05B	Enovis
EV/Revenue Ratio	1.40	1.39	Enovis
Gross Profit Margin (TTM)	52.34%	59.45%	Enovis
Revenue per Share (TTM)	$2	$39	Enovis
Earnings per Share (Diluted)	$-0.05	$-14.95	Cytek Biosciences
Beta (Stock Volatility)	1.35	1.81	Cytek Biosciences

Performance

Key Stats

Valuation

Financials

Short Interest

Dividends

Cytek Biosciences vs Enovis Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock	1D	1W	1M	3M	6M	YTD
Cytek Biosciences	-1.95%	10.71%	17.49%	6.33%	-21.75%	-38.66%
Enovis	-0.28%	10.49%	-18.13%	-14.03%	-36.06%	-35.80%

Long-term Returns

Stock	1Y	3Y	5Y	10Y	15Y	20Y
Cytek Biosciences	-22.80%	-72.95%	-78.52%	-78.52%	-78.52%	-78.52%
Enovis	-34.47%	-52.47%	-52.16%	-58.10%	33.33%	-19.39%

Performance Comparison

This comparison requires JavaScript for dynamic charts and real-time data. For complete performance analysis, visit the individual stock overview pages:

Cytek Biosciences (CTKB): View Full Stock Overview

Enovis (ENOV): View Full Stock Overview

The individual stock overview pages contain detailed performance metrics, historical charts, financial data, and comparison tools that work without JavaScript.

Key Performance Metrics Available:

Daily, weekly, monthly, and yearly returns
52-week high and low prices
Market capitalization and valuation ratios
Financial health and profitability metrics
Dividend history and yield information

Performance & Financial Health Analysis: Cytek Biosciences vs Enovis

Metric	CTKB	ENOV
Market Information
Market Cap i	$512.71M	$1.63B
Market Cap Category	Small cap	Small cap
10 Day Avg. Volume i	1,343,420	1,375,280
90 Day Avg. Volume i	1,088,190	1,733,377
Last Close	$4.03	$28.44
52 Week Range	$2.37 - $7.63	$25.47 - $49.83
% from 52W High	-47.18%	-42.93%
All-Time High	$28.70 (Sep 13, 2021)	$129.72 (Jun 09, 2014)
% from All-Time High	-85.96%	-78.08%
Growth Metrics
Quarterly Revenue Growth	-0.02%	0.08%
Quarterly Earnings Growth	-0.02%	0.08%
Financial Health
Profit Margin (TTM) i	-0.03%	-0.38%
Operating Margin (TTM) i	-0.23%	0.02%
Return on Equity (TTM) i	-0.02%	-0.28%
Debt to Equity (MRQ) i	6.27	56.75
Cash & Liquidity
Book Value per Share (MRQ)	$2.97	$45.11
Cash per Share (MRQ)	$2.06	$0.77
Operating Cash Flow (TTM) i	$15.20M	$188.06M
Levered Free Cash Flow (TTM) i	$18.52M	$65.68M
Dividends
Last 12-Month Dividend Yield i	N/A	N/A
Last 12-Month Dividend i	N/A	$0.00

Valuation & Enterprise Metrics Analysis: Cytek Biosciences vs Enovis

Metric	CTKB	ENOV
Price Ratios
P/E Ratio (TTM) i	374.50	-1.90
Forward P/E i	67.17	9.00
PEG Ratio i	67.17	9.00
Price to Sales (TTM) i	2.62	0.74
Price to Book (MRQ) i	1.36	0.63
Market Capitalization
Market Capitalization i	$512.71M	$1.63B
Enterprise Value i	$274.37M	$3.05B
Enterprise Value Metrics
Enterprise to Revenue i	1.40	1.39
Enterprise to EBITDA i	-12.48	8.41
Risk & Other Metrics
Beta i	1.35	1.81
Book Value per Share (MRQ) i	$2.97	$45.11

Financial Statements Comparison: Cytek Biosciences vs Enovis

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)	CTKB	ENOV
Revenue/Sales i	$45.60M	$558.83M
Cost of Goods Sold i	$21.74M	$226.61M
Gross Profit i	$23.87M	$332.23M
Research & Development i	$8.83M	$28.53M
Operating Income (EBIT) i	$-10.62M	$-42.91M
EBITDA i	$-3.37M	$27.14M
Pre-Tax Income i	$-6.78M	$-57.35M
Income Tax i	$-1.19M	$-1.77M
Net Income (Profit) i	$-5.58M	$-55.71M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)	CTKB	ENOV
Cash & Equivalents i	$95.30M	$38.46M
Total Current Assets i	$380.50M	$1.22B
Total Current Liabilities i	$67.69M	$477.42M
Long-Term Debt i	$8.37M	$1.42B
Total Shareholders Equity i	$379.62M	$2.62B
Retained Earnings i	$-46.60M	$-338.99M
Property, Plant & Equipment i	$21.62M	$492.24M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)	CTKB	ENOV
Operating Cash Flow i	$3.22M	$-1.07M
Capital Expenditures i	$-816,000	$-43.26M
Free Cash Flow i	$-976,000	$-44.86M
Debt Repayment i	$-1.52M	$-15.44M
Common Stock Repurchase i	$-10.63M	N/A

Short Interest & Institutional Ownership Analysis

Metric	CTKB	ENOV
Shares Short i	5.65M	7.43M
Short Ratio i	4.54	4.68
Short % of Float i	0.06%	0.20%
Average Daily Volume (10 Day) i	1,343,420	1,375,280
Average Daily Volume (90 Day) i	1,088,190	1,733,377
Shares Outstanding i	129.21M	55.88M
Float Shares i	108.71M	56.44M
% Held by Insiders i	0.09%	0.02%
% Held by Institutions i	0.60%	1.08%

Dividend Analysis & Yield Comparison: Cytek Biosciences vs Enovis

Metric	CTKB	ENOV
Last 12-Month Dividend i	N/A	$0.00
Last 12-Month Dividend Yield i	N/A	N/A
3-Year Avg Annual Dividend i	N/A	$0.00
3-Year Avg Dividend Yield i	N/A	N/A
3-Year Total Dividends i	N/A	$0.00
Ex-Dividend Date	N/A	N/A

Cytek Biosciences [CTKB] vs Enovis [ENOV] Detailed Stock Comparison